PE20150710A1 - Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion - Google Patents

Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion

Info

Publication number
PE20150710A1
PE20150710A1 PE2015000210A PE2015000210A PE20150710A1 PE 20150710 A1 PE20150710 A1 PE 20150710A1 PE 2015000210 A PE2015000210 A PE 2015000210A PE 2015000210 A PE2015000210 A PE 2015000210A PE 20150710 A1 PE20150710 A1 PE 20150710A1
Authority
PE
Peru
Prior art keywords
composition
layer
microspheres
active principle
pharmaceutical composition
Prior art date
Application number
PE2015000210A
Other languages
English (en)
Inventor
Hernandez Gustavo Barranco
Guiza Maria Del Coral Luna
Arroyo Hector Senosiain
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50435594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150710(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Publication of PE20150710A1 publication Critical patent/PE20150710A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Referida a una composicion en forma de microparticulas que consta de: a) un nucleo inerte, b) una primera capa de principio activo formada por aspersion sobre el nucleo inerte que comprende al menos un polimero adhesivo o aglutinante y al menos un lubricante deslizante y c) opcionalmente un segundo recubrimiento que comprende una o mas capas de farmaco(s) y/o excipiente(s) farmaceuticamente aceptable(s). El principio activo de la primera capa es hidroclorotiazida, vitamina B1, rosuvastatina, simvastatina, entre otros; el polimero adhesivo es polivinilpirrolidona, metacrilatos, acido alginico, entre otros y el lubricante es acetato de sodio, cloruro de sodio, almidon, entre otros. Dicha composicion es util para el tratamiento de condiciones resultantes de retencion excesiva de agua y/o electrolitos, enfermedades cardiovasculares, enfermedades renovasculares, diabetes, disfunciones endoteliales, cirrosis, preeclampsia, nefropatia, enfermedad vascular periferica e hipertension, entre otras
PE2015000210A 2012-08-17 2013-08-16 Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion PE20150710A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2012009583A MX351059B (es) 2012-08-17 2012-08-17 Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion.

Publications (1)

Publication Number Publication Date
PE20150710A1 true PE20150710A1 (es) 2015-05-28

Family

ID=50435594

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000210A PE20150710A1 (es) 2012-08-17 2013-08-16 Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion

Country Status (8)

Country Link
CL (1) CL2015000375A1 (es)
CO (1) CO7310526A2 (es)
CR (1) CR20150077A (es)
DO (1) DOP2015000028A (es)
GT (1) GT201500035A (es)
MX (1) MX351059B (es)
PE (1) PE20150710A1 (es)
WO (1) WO2014027334A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2978859T1 (sl) 2013-03-27 2018-10-30 F. Hoffmann-La Roche Ag Genetski označevalci za napovedovanje odzivnosti na terapijo
JP6854752B2 (ja) 2014-07-30 2021-04-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｄｌ上昇剤又はｈｄｌ模倣剤を用いた治療に対する応答性を予測するための遺伝マーカー
CN104523710B (zh) * 2014-12-30 2018-05-25 石药集团欧意药业有限公司 一种硫酸氢氯吡格雷阿司匹林复合双层片及其制备方法
KR101710441B1 (ko) * 2015-12-28 2017-02-28 신풍제약주식회사 안정성 및 용출성이 향상된 정제
EP3582777A4 (en) 2017-02-17 2020-12-23 Unichem Laboratories Ltd PHARMACEUTICAL COMPOSITION OF APIXABAN
CN106821996A (zh) * 2017-03-01 2017-06-13 华益药业科技(安徽)有限公司 马来酸依那普利颗粒剂及其制备方法
JP7382957B2 (ja) * 2018-04-16 2023-11-17 ブリストル－マイヤーズ スクイブ カンパニー アピキサバン製剤
CA3166756A1 (en) * 2020-02-19 2021-08-26 Nano Pharmasolutions, Inc. Therapeutic agent nanoparticles and methods of preparation
US11833133B2 (en) * 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition
CN113413364A (zh) * 2021-05-31 2021-09-21 辰欣药业股份有限公司 一种依诺肝素钠注射液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2640165A1 (en) * 2006-01-27 2007-08-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivid Ed Trinity Of Queen Elizabeth Near Dublin A method of producing porous microparticles
MXPA06010972A (es) * 2006-09-25 2009-04-17 World Trade Imp Export Wtie Ag Proceso para estabilizacion de famotidina.
WO2008045006A1 (en) * 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
MX2007008440A (es) * 2007-07-11 2009-02-18 Senosiain S A De C V Lab Composicion farmaceutica combinada.

Also Published As

Publication number Publication date
WO2014027334A3 (es) 2014-04-10
MX2012009583A (es) 2014-02-26
GT201500035A (es) 2017-10-24
CL2015000375A1 (es) 2015-07-10
CR20150077A (es) 2015-05-13
CO7310526A2 (es) 2015-06-30
MX351059B (es) 2017-09-29
DOP2015000028A (es) 2015-03-15
WO2014027334A2 (es) 2014-02-20

Similar Documents

Publication Publication Date Title
PE20150710A1 (es) Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion
RU2015124694A (ru) Саморегулируемое высвобождение фармацевтического ингредиента
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
JP2010222367A5 (es)
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
JP2012255026A5 (es)
EA201291247A1 (ru) ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ В ФОРМЕ ДВУХСЛОЙНЫХ ТАБЛЕТОК, СОДЕРЖАЩИХ ИНГИБИТОР HMG-CoA РЕДУКТАЗЫ И ИРБЕСАРТАН
UA117103C2 (uk) Сполука, яка має активність агоніста глюкагону
AR087360A1 (es) Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
PE20130574A1 (es) Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
JP2012517449A5 (es)
RU2015102772A (ru) Бензодиазелипы для мелкоклеточного рака легкого
MX2014012734A (es) Formulacion inyectable.
EP2796450A4 (en) 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES
WO2015038552A3 (en) Aspirin formulation for increased efficacy
JP2014510782A5 (es)
JP2018039810A5 (es)
PL2865664T3 (pl) Nowy związek mający zdolność hamowania enzymu 11ß-HSD1, lub jego farmaceutycznie dopuszczalna sól, sposób wytwarzania go, i kompozycja farmaceutyczna zawierająca go jako składnik aktywny
CL2014002896A1 (es) Una formulacion farmaceutica en la forma de una tableta recubierta que consiste de a) un nucleo obtenido a partir de una co-mezcla de manitol, croscarmelosa de sodio y al menos un compuestos activo, y b) un recubrimiento el cual se aplica en la forma de una solucion acuosa o que contiene agua y alcohol, y donde la tableta se desintegra rapidamente en presencia de humedad; y su proceso de preparacion.
JP2014062109A5 (es)
AR084882A1 (es) Compuesto de 1-azabiciclo[2.2.2]octano y usos para el tratamiento de esquizofrenia
FI3345604T3 (fi) Nalmefeeni alkoholikulutuksen vähentämiseksi spesifisissä kohdepopulaatioissa
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
PE20110925A1 (es) Formulacion galenica que comprende alisquireno y proceso para su preparacion mediante granulacion de extrusion fundida
JP2014509637A5 (es)

Legal Events

Date Code Title Description
FG Grant, registration